CN105853994A - Oral liquid for resisting CT radiation and preparation method thereof - Google Patents
Oral liquid for resisting CT radiation and preparation method thereof Download PDFInfo
- Publication number
- CN105853994A CN105853994A CN201610286995.1A CN201610286995A CN105853994A CN 105853994 A CN105853994 A CN 105853994A CN 201610286995 A CN201610286995 A CN 201610286995A CN 105853994 A CN105853994 A CN 105853994A
- Authority
- CN
- China
- Prior art keywords
- oral liquid
- radiation
- resisting
- acid
- refers
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000007788 liquid Substances 0.000 title claims abstract description 44
- 230000005855 radiation Effects 0.000 title claims abstract description 39
- 238000002360 preparation method Methods 0.000 title claims abstract description 11
- 239000003814 drug Substances 0.000 claims abstract description 38
- 102000001189 Cyclic Peptides Human genes 0.000 claims abstract description 25
- 108010069514 Cyclic Peptides Proteins 0.000 claims abstract description 25
- ZQSIJRDFPHDXIC-UHFFFAOYSA-N daidzein Chemical compound C1=CC(O)=CC=C1C1=COC2=CC(O)=CC=C2C1=O ZQSIJRDFPHDXIC-UHFFFAOYSA-N 0.000 claims abstract description 22
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 claims abstract description 22
- XMGQYMWWDOXHJM-UHFFFAOYSA-N limonene Chemical compound CC(=C)C1CCC(C)=CC1 XMGQYMWWDOXHJM-UHFFFAOYSA-N 0.000 claims abstract description 22
- LNTHITQWFMADLM-UHFFFAOYSA-N gallic acid Chemical compound OC(=O)C1=CC(O)=C(O)C(O)=C1 LNTHITQWFMADLM-UHFFFAOYSA-N 0.000 claims abstract description 20
- 239000003755 preservative agent Substances 0.000 claims abstract description 20
- 230000002335 preservative effect Effects 0.000 claims abstract description 20
- 239000004094 surface-active agent Substances 0.000 claims abstract description 16
- OILXMJHPFNGGTO-UHFFFAOYSA-N (22E)-(24xi)-24-methylcholesta-5,22-dien-3beta-ol Natural products C1C=C2CC(O)CCC2(C)C2C1C1CCC(C(C)C=CC(C)C(C)C)C1(C)CC2 OILXMJHPFNGGTO-UHFFFAOYSA-N 0.000 claims abstract description 13
- OQMZNAMGEHIHNN-UHFFFAOYSA-N 7-Dehydrostigmasterol Natural products C1C(O)CCC2(C)C(CCC3(C(C(C)C=CC(CC)C(C)C)CCC33)C)C3=CC=C21 OQMZNAMGEHIHNN-UHFFFAOYSA-N 0.000 claims abstract description 13
- HZYXFRGVBOPPNZ-UHFFFAOYSA-N UNPD88870 Natural products C1C=C2CC(O)CCC2(C)C2C1C1CCC(C(C)=CCC(CC)C(C)C)C1(C)CC2 HZYXFRGVBOPPNZ-UHFFFAOYSA-N 0.000 claims abstract description 13
- LGJMUZUPVCAVPU-UHFFFAOYSA-N beta-Sitostanol Natural products C1CC2CC(O)CCC2(C)C2C1C1CCC(C(C)CCC(CC)C(C)C)C1(C)CC2 LGJMUZUPVCAVPU-UHFFFAOYSA-N 0.000 claims abstract description 13
- HCXVJBMSMIARIN-PHZDYDNGSA-N stigmasterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)/C=C/[C@@H](CC)C(C)C)[C@@]1(C)CC2 HCXVJBMSMIARIN-PHZDYDNGSA-N 0.000 claims abstract description 13
- 229940032091 stigmasterol Drugs 0.000 claims abstract description 13
- BFDNMXAIBMJLBB-UHFFFAOYSA-N stigmasterol Natural products CCC(C=CC(C)C1CCCC2C3CC=C4CC(O)CCC4(C)C3CCC12C)C(C)C BFDNMXAIBMJLBB-UHFFFAOYSA-N 0.000 claims abstract description 13
- 235000016831 stigmasterol Nutrition 0.000 claims abstract description 13
- MIJYXULNPSFWEK-GTOFXWBISA-N 3beta-hydroxyolean-12-en-28-oic acid Chemical compound C1C[C@H](O)C(C)(C)[C@@H]2CC[C@@]3(C)[C@]4(C)CC[C@@]5(C(O)=O)CCC(C)(C)C[C@H]5C4=CC[C@@H]3[C@]21C MIJYXULNPSFWEK-GTOFXWBISA-N 0.000 claims abstract description 11
- 239000004475 Arginine Substances 0.000 claims abstract description 11
- JKLISIRFYWXLQG-UHFFFAOYSA-N Epioleonolsaeure Natural products C1CC(O)C(C)(C)C2CCC3(C)C4(C)CCC5(C(O)=O)CCC(C)(C)CC5C4CCC3C21C JKLISIRFYWXLQG-UHFFFAOYSA-N 0.000 claims abstract description 11
- 229920001491 Lentinan Polymers 0.000 claims abstract description 11
- OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 claims abstract description 11
- YBRJHZPWOMJYKQ-UHFFFAOYSA-N Oleanolic acid Natural products CC1(C)CC2C3=CCC4C5(C)CCC(O)C(C)(C)C5CCC4(C)C3(C)CCC2(C1)C(=O)O YBRJHZPWOMJYKQ-UHFFFAOYSA-N 0.000 claims abstract description 11
- MIJYXULNPSFWEK-UHFFFAOYSA-N Oleanolinsaeure Natural products C1CC(O)C(C)(C)C2CCC3(C)C4(C)CCC5(C(O)=O)CCC(C)(C)CC5C4=CCC3C21C MIJYXULNPSFWEK-UHFFFAOYSA-N 0.000 claims abstract description 11
- 229930003451 Vitamin B1 Natural products 0.000 claims abstract description 11
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 claims abstract description 11
- 235000007240 daidzein Nutrition 0.000 claims abstract description 11
- VJJPUSNTGOMMGY-MRVIYFEKSA-N etoposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@H](C)OC[C@H]4O3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 VJJPUSNTGOMMGY-MRVIYFEKSA-N 0.000 claims abstract description 11
- 229960005420 etoposide Drugs 0.000 claims abstract description 11
- 229960000304 folic acid Drugs 0.000 claims abstract description 11
- 235000019152 folic acid Nutrition 0.000 claims abstract description 11
- 239000011724 folic acid Substances 0.000 claims abstract description 11
- 229940115286 lentinan Drugs 0.000 claims abstract description 11
- 229940087305 limonene Drugs 0.000 claims abstract description 11
- 235000001510 limonene Nutrition 0.000 claims abstract description 11
- 229940100243 oleanolic acid Drugs 0.000 claims abstract description 11
- HZLWUYJLOIAQFC-UHFFFAOYSA-N prosapogenin PS-A Natural products C12CC(C)(C)CCC2(C(O)=O)CCC(C2(CCC3C4(C)C)C)(C)C1=CCC2C3(C)CCC4OC1OCC(O)C(O)C1O HZLWUYJLOIAQFC-UHFFFAOYSA-N 0.000 claims abstract description 11
- 239000008213 purified water Substances 0.000 claims abstract description 11
- 229960003495 thiamine Drugs 0.000 claims abstract description 11
- DPJRMOMPQZCRJU-UHFFFAOYSA-M thiamine hydrochloride Chemical compound Cl.[Cl-].CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N DPJRMOMPQZCRJU-UHFFFAOYSA-M 0.000 claims abstract description 11
- 239000011691 vitamin B1 Substances 0.000 claims abstract description 11
- 235000010374 vitamin B1 Nutrition 0.000 claims abstract description 11
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 11
- HIMJIPRMECETLJ-UHFFFAOYSA-N Wogonin Natural products COc1cc(O)c(O)c2C(=O)C=C(Oc12)c3ccccc3 HIMJIPRMECETLJ-UHFFFAOYSA-N 0.000 claims abstract description 10
- 229940074391 gallic acid Drugs 0.000 claims abstract description 10
- 235000004515 gallic acid Nutrition 0.000 claims abstract description 10
- XLTFNNCXVBYBSX-UHFFFAOYSA-N wogonin Chemical compound COC1=C(O)C=C(O)C(C(C=2)=O)=C1OC=2C1=CC=CC=C1 XLTFNNCXVBYBSX-UHFFFAOYSA-N 0.000 claims abstract description 10
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 claims abstract description 6
- 229960003121 arginine Drugs 0.000 claims abstract description 6
- 235000012907 honey Nutrition 0.000 claims abstract description 6
- 239000003795 chemical substances by application Substances 0.000 claims description 19
- 238000002156 mixing Methods 0.000 claims description 16
- 239000000843 powder Substances 0.000 claims description 16
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 13
- 238000000034 method Methods 0.000 claims description 7
- 102000004169 proteins and genes Human genes 0.000 claims description 7
- 108090000623 proteins and genes Proteins 0.000 claims description 7
- 239000002671 adjuvant Substances 0.000 claims description 5
- 238000013019 agitation Methods 0.000 claims description 5
- 150000001875 compounds Chemical class 0.000 claims description 5
- 239000013078 crystal Substances 0.000 claims description 5
- 239000012528 membrane Substances 0.000 claims description 5
- 230000008569 process Effects 0.000 claims description 5
- 210000000582 semen Anatomy 0.000 claims description 5
- 230000001954 sterilising effect Effects 0.000 claims description 5
- 238000004659 sterilization and disinfection Methods 0.000 claims description 5
- 239000000284 extract Substances 0.000 claims description 4
- LDVVTQMJQSCDMK-UHFFFAOYSA-N 1,3-dihydroxypropan-2-yl formate Chemical compound OCC(CO)OC=O LDVVTQMJQSCDMK-UHFFFAOYSA-N 0.000 claims description 3
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims description 3
- 229930195725 Mannitol Natural products 0.000 claims description 3
- KGUHOFWIXKIURA-VQXBOQCVSA-N [(2r,3s,4s,5r,6r)-6-[(2s,3s,4s,5r)-3,4-dihydroxy-2,5-bis(hydroxymethyl)oxolan-2-yl]oxy-3,4,5-trihydroxyoxan-2-yl]methyl dodecanoate Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](COC(=O)CCCCCCCCCCC)O[C@@H]1O[C@@]1(CO)[C@@H](O)[C@H](O)[C@@H](CO)O1 KGUHOFWIXKIURA-VQXBOQCVSA-N 0.000 claims description 3
- 235000009508 confectionery Nutrition 0.000 claims description 3
- 235000014113 dietary fatty acids Nutrition 0.000 claims description 3
- BEFDCLMNVWHSGT-UHFFFAOYSA-N ethenylcyclopentane Chemical compound C=CC1CCCC1 BEFDCLMNVWHSGT-UHFFFAOYSA-N 0.000 claims description 3
- 229930195729 fatty acid Natural products 0.000 claims description 3
- 239000000194 fatty acid Substances 0.000 claims description 3
- 150000004665 fatty acids Chemical class 0.000 claims description 3
- 239000000594 mannitol Substances 0.000 claims description 3
- 235000010355 mannitol Nutrition 0.000 claims description 3
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 claims description 3
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 claims description 3
- 229920000223 polyglycerol Polymers 0.000 claims description 3
- WXMKPNITSTVMEF-UHFFFAOYSA-M sodium benzoate Chemical compound [Na+].[O-]C(=O)C1=CC=CC=C1 WXMKPNITSTVMEF-UHFFFAOYSA-M 0.000 claims description 3
- 235000010234 sodium benzoate Nutrition 0.000 claims description 3
- 239000004299 sodium benzoate Substances 0.000 claims description 3
- 235000010199 sorbic acid Nutrition 0.000 claims description 3
- 239000004334 sorbic acid Substances 0.000 claims description 3
- 229940075582 sorbic acid Drugs 0.000 claims description 3
- 229940032085 sucrose monolaurate Drugs 0.000 claims description 3
- IPQKDIRUZHOIOM-UHFFFAOYSA-N Oroxin A Natural products OC1C(O)C(O)C(CO)OC1OC(C(=C1O)O)=CC2=C1C(=O)C=C(C=1C=CC=CC=1)O2 IPQKDIRUZHOIOM-UHFFFAOYSA-N 0.000 claims 1
- 241001593750 Turcica Species 0.000 claims 1
- 239000002253 acid Substances 0.000 claims 1
- IKIIZLYTISPENI-ZFORQUDYSA-N baicalin Chemical compound O1[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1OC(C(=C1O)O)=CC2=C1C(=O)C=C(C=1C=CC=CC=1)O2 IKIIZLYTISPENI-ZFORQUDYSA-N 0.000 claims 1
- 229960003321 baicalin Drugs 0.000 claims 1
- AQHDANHUMGXSJZ-UHFFFAOYSA-N baicalin Natural products OC1C(O)C(C(O)CO)OC1OC(C(=C1O)O)=CC2=C1C(=O)C=C(C=1C=CC=CC=1)O2 AQHDANHUMGXSJZ-UHFFFAOYSA-N 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 31
- 230000036039 immunity Effects 0.000 abstract description 12
- 239000000463 material Substances 0.000 abstract description 9
- 210000004027 cell Anatomy 0.000 abstract description 8
- 201000010099 disease Diseases 0.000 abstract description 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 6
- 230000002708 enhancing effect Effects 0.000 abstract description 5
- 230000006907 apoptotic process Effects 0.000 abstract description 3
- 206010067484 Adverse reaction Diseases 0.000 abstract description 2
- 230000006838 adverse reaction Effects 0.000 abstract description 2
- 230000003471 anti-radiation Effects 0.000 abstract 1
- 235000009697 arginine Nutrition 0.000 abstract 1
- 230000007012 clinical effect Effects 0.000 abstract 1
- 235000003599 food sweetener Nutrition 0.000 abstract 1
- 210000002865 immune cell Anatomy 0.000 abstract 1
- 239000002904 solvent Substances 0.000 abstract 1
- 239000003765 sweetening agent Substances 0.000 abstract 1
- 102000004190 Enzymes Human genes 0.000 description 12
- 108090000790 Enzymes Proteins 0.000 description 12
- 230000000844 anti-bacterial effect Effects 0.000 description 8
- 239000000203 mixture Substances 0.000 description 8
- 210000004369 blood Anatomy 0.000 description 7
- 239000008280 blood Substances 0.000 description 7
- 241000699670 Mus sp. Species 0.000 description 6
- 235000018102 proteins Nutrition 0.000 description 6
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 4
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 4
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 4
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 4
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 4
- 238000010521 absorption reaction Methods 0.000 description 4
- 230000009471 action Effects 0.000 description 4
- 230000000259 anti-tumor effect Effects 0.000 description 4
- 230000001174 ascending effect Effects 0.000 description 4
- 230000005540 biological transmission Effects 0.000 description 4
- 210000001124 body fluid Anatomy 0.000 description 4
- 239000010839 body fluid Substances 0.000 description 4
- 239000011575 calcium Substances 0.000 description 4
- 229910052791 calcium Inorganic materials 0.000 description 4
- 210000000170 cell membrane Anatomy 0.000 description 4
- 238000005352 clarification Methods 0.000 description 4
- 239000010949 copper Substances 0.000 description 4
- 229910052802 copper Inorganic materials 0.000 description 4
- 230000006378 damage Effects 0.000 description 4
- 230000007812 deficiency Effects 0.000 description 4
- 230000036425 denaturation Effects 0.000 description 4
- 238000004925 denaturation Methods 0.000 description 4
- 208000002925 dental caries Diseases 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- 229940011871 estrogen Drugs 0.000 description 4
- 239000000262 estrogen Substances 0.000 description 4
- 206010016256 fatigue Diseases 0.000 description 4
- 238000001914 filtration Methods 0.000 description 4
- 239000008187 granular material Substances 0.000 description 4
- 230000036541 health Effects 0.000 description 4
- 230000003834 intracellular effect Effects 0.000 description 4
- 208000030208 low-grade fever Diseases 0.000 description 4
- 210000004072 lung Anatomy 0.000 description 4
- 201000004792 malaria Diseases 0.000 description 4
- WPBNNNQJVZRUHP-UHFFFAOYSA-L manganese(2+);methyl n-[[2-(methoxycarbonylcarbamothioylamino)phenyl]carbamothioyl]carbamate;n-[2-(sulfidocarbothioylamino)ethyl]carbamodithioate Chemical compound [Mn+2].[S-]C(=S)NCCNC([S-])=S.COC(=O)NC(=S)NC1=CC=CC=C1NC(=S)NC(=O)OC WPBNNNQJVZRUHP-UHFFFAOYSA-L 0.000 description 4
- 238000004519 manufacturing process Methods 0.000 description 4
- 230000000813 microbial effect Effects 0.000 description 4
- 244000005700 microbiome Species 0.000 description 4
- 239000002736 nonionic surfactant Substances 0.000 description 4
- 231100000252 nontoxic Toxicity 0.000 description 4
- 230000003000 nontoxic effect Effects 0.000 description 4
- 238000011275 oncology therapy Methods 0.000 description 4
- 150000007524 organic acids Chemical class 0.000 description 4
- 239000002245 particle Substances 0.000 description 4
- 238000005502 peroxidation Methods 0.000 description 4
- 239000011574 phosphorus Substances 0.000 description 4
- 229910052698 phosphorus Inorganic materials 0.000 description 4
- 239000011591 potassium Substances 0.000 description 4
- 229910052700 potassium Inorganic materials 0.000 description 4
- 230000001737 promoting effect Effects 0.000 description 4
- 238000010298 pulverizing process Methods 0.000 description 4
- 238000000746 purification Methods 0.000 description 4
- 230000000241 respiratory effect Effects 0.000 description 4
- 238000004062 sedimentation Methods 0.000 description 4
- 238000000926 separation method Methods 0.000 description 4
- 230000003860 sleep quality Effects 0.000 description 4
- 210000000952 spleen Anatomy 0.000 description 4
- 230000001629 suppression Effects 0.000 description 4
- 239000000725 suspension Substances 0.000 description 4
- 239000011573 trace mineral Substances 0.000 description 4
- 235000013619 trace mineral Nutrition 0.000 description 4
- 229940088594 vitamin Drugs 0.000 description 4
- 229930003231 vitamin Natural products 0.000 description 4
- 235000013343 vitamin Nutrition 0.000 description 4
- 239000011782 vitamin Substances 0.000 description 4
- 150000003722 vitamin derivatives Chemical class 0.000 description 4
- 241000208340 Araliaceae Species 0.000 description 3
- 208000024172 Cardiovascular disease Diseases 0.000 description 3
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 description 3
- 235000003140 Panax quinquefolius Nutrition 0.000 description 3
- 244000046052 Phaseolus vulgaris Species 0.000 description 3
- 235000010627 Phaseolus vulgaris Nutrition 0.000 description 3
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 3
- 208000027418 Wounds and injury Diseases 0.000 description 3
- 230000003203 everyday effect Effects 0.000 description 3
- 235000008434 ginseng Nutrition 0.000 description 3
- 229910017053 inorganic salt Inorganic materials 0.000 description 3
- 230000000050 nutritive effect Effects 0.000 description 3
- 150000003431 steroids Chemical class 0.000 description 3
- 235000019605 sweet taste sensations Nutrition 0.000 description 3
- 208000005623 Carcinogenesis Diseases 0.000 description 2
- 241000699666 Mus <mouse, genus> Species 0.000 description 2
- 230000002159 abnormal effect Effects 0.000 description 2
- 230000002421 anti-septic effect Effects 0.000 description 2
- 230000017531 blood circulation Effects 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 201000011510 cancer Diseases 0.000 description 2
- 230000036952 cancer formation Effects 0.000 description 2
- 231100000504 carcinogenesis Toxicity 0.000 description 2
- 238000002591 computed tomography Methods 0.000 description 2
- 238000003745 diagnosis Methods 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 230000002607 hemopoietic effect Effects 0.000 description 2
- 208000014674 injury Diseases 0.000 description 2
- 238000007689 inspection Methods 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- 230000002285 radioactive effect Effects 0.000 description 2
- 238000002604 ultrasonography Methods 0.000 description 2
- 206010059245 Angiopathy Diseases 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 208000002177 Cataract Diseases 0.000 description 1
- 206010008111 Cerebral haemorrhage Diseases 0.000 description 1
- 208000032170 Congenital Abnormalities Diseases 0.000 description 1
- 101100108327 Escherichia coli (strain K12) melA gene Proteins 0.000 description 1
- 206010018691 Granuloma Diseases 0.000 description 1
- 206010053759 Growth retardation Diseases 0.000 description 1
- 206010018852 Haematoma Diseases 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 208000030852 Parasitic disease Diseases 0.000 description 1
- 208000012287 Prolapse Diseases 0.000 description 1
- 206010000269 abscess Diseases 0.000 description 1
- 235000001014 amino acid Nutrition 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 230000001363 autoimmune Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 230000004641 brain development Effects 0.000 description 1
- 208000029028 brain injury Diseases 0.000 description 1
- 230000000711 cancerogenic effect Effects 0.000 description 1
- 231100000315 carcinogenic Toxicity 0.000 description 1
- 206010008118 cerebral infarction Diseases 0.000 description 1
- 208000026106 cerebrovascular disease Diseases 0.000 description 1
- 210000000695 crystalline len Anatomy 0.000 description 1
- 230000000857 drug effect Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 210000003754 fetus Anatomy 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 210000002149 gonad Anatomy 0.000 description 1
- 231100000001 growth retardation Toxicity 0.000 description 1
- 210000003677 hemocyte Anatomy 0.000 description 1
- 229940000351 hemocyte Drugs 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 208000032839 leukemia Diseases 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 210000001161 mammalian embryo Anatomy 0.000 description 1
- 210000005075 mammary gland Anatomy 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 239000000941 radioactive substance Substances 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 201000011096 spinal cancer Diseases 0.000 description 1
- 208000010110 spontaneous platelet aggregation Diseases 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 210000001685 thyroid gland Anatomy 0.000 description 1
- 238000012795 verification Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/01—Hydrocarbons
- A61K31/015—Hydrocarbons carbocyclic
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
- A61K31/51—Thiamines, e.g. vitamin B1
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/56—Materials from animals other than mammals
- A61K35/63—Arthropods
- A61K35/64—Insects, e.g. bees, wasps or fleas
- A61K35/644—Beeswax; Propolis; Royal jelly; Honey
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
- A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/36—Caryophyllaceae (Pink family), e.g. babysbreath or soapwort
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Molecular Biology (AREA)
- Insects & Arthropods (AREA)
- Animal Husbandry (AREA)
- Gastroenterology & Hepatology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Zoology (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
The invention discloses oral liquid for resisting CT radiation and a preparation method thereof. The oral liquid is mainly prepared from wogonin, radix pseudostellariae cyclic peptide, folic acid, etoposide, stigmasterol, oleanolic acid, daidzein, gallic acid, limonene, vitamin B1, arginine, lentinan, honey and purified water. The oral liquid further comprises auxiliary materials of a solubilizer, a preservative, a surfactant and a sweetening agent. The oral liquid has the effects of achieving good radiation resistance, enhancing immunity and preventing cell cancerization, the immunity of the human body is enhanced, apoptosis of immune cells is restrained, and an anti-radiation effect is achieved. The oral liquid is suitable for people in contact with CT radiation for a long time, the medicine effect is mild and stable, no obvious adverse reaction is generated, and a good clinical effect is achieved for preventing diseases caused by CT radiation.
Description
Technical field
The present invention relates to radiate disease practical technique field, be specifically related to a kind of oral liquid resisting CT radiation
And preparation method thereof.
Background technology
CT i.e. CT scan, it is to utilize the X-ray beam of Accurate collimation, gamma-rays, ultrasound wave
Deng, the detector high with sensitivity together makees profile scanning one by one around a certain position of human body,
There is sweep time fast, the features such as image is clear, can be used for the inspection of multiple disease；According to the ray used
Difference can be divided into: X ray CT (X-CT), ultrasound computed tomography (UCT) and gamma-rays CT (γ-CT) etc..
The biggest assosting effect is played in its diagnosis to disease clinically, such as abscess and granuloma, parasitic disease, outer
Wound property hematoma and brain injury, cerebral infarction and cerebral hemorrhage and the disease such as intraspinal tumor and prolapse of intervertebral disc.Sick diagnosis
Effective, diagnose the most reliable.
CT examination has the biggest side effect to produce simultaneously, and in the environment of High-Field, patient can be brought sternly by these things
The injury of weight.Gonad, eye lens, mammary gland and thyroid in human body are especially sensitive to ray, if subjected to long
Time, high-dose irradiation, may cause cataract, sterillization, growth retardation, even induce malignant tumor
Or leukemia.The impact on fetus of the X-ray radiation, relatively easily causes embryo maimed person, fetal anomaly, brain development
Bad, and childhood period cancer probability increase.The most generally at the conceived initial stage, it is exposed among X-ray,
It is easier to cause great injury, closer to expected date of confinement, affects the least.One time body CT can kill few
Number hemocyte, but also result in DNA break, substantially can repair, but have the probability made mistakes, make mistakes
After the probability of distortion that has, have carcinogenic probability after distortion.Although CT examination the most once is to human body
Damage can be eliminated by the immune system of human body, but some client need CT examination the most repeatedly, or
Person's CT practitioner's Long Term Contact radioactive source, works in the environment having radioactive source to remain, can cause human immunity
Ability declines, and leukocyte reduces, and patient's resume speed slows down, and What is more can produce cell carcinogenesis, and this just needs
Just to improve human body immunity using safely and effectively medicine, to improve blood circulation and nervus centralis simultaneously
Hemopoietic system function, alleviates isotope, the ray infringement to body's immunity, and suppresses immunocyte
Apoptosis and there is radiation resistance.
Summary of the invention
Present invention solves the technical problem that and be to provide a kind of oral liquid resisting CT radiation and preparation method thereof.
For solve above-mentioned technical problem, the technical solution adopted in the present invention is as follows: a kind of resist CT radiation
Oral liquid, described oral liquid specifically include that wogonin 1.2～1.8%, Radix pseudostellariae cyclic peptides 2.4～3.2%,
Folic acid 0.8～1.6%, etoposide 0.05～0.09%, stigmasterol 0.6～1.0%, oleanolic acid 0.5～0.8%,
Daidzein 0.8～1.2%, gallic acid 0.2～0.5%, limonene 0.3～0.6%, vitamin B1 0.08～
0.12%, arginine 0.15～0.35%, lentinan 1.4～1.8%, Mel 5～9%, surplus are purified water；
Described oral liquid also includes adjuvant: preservative 0.02～0.05%, surfactant 0.35～0.55%, sweet
Taste agent 3～5%.
Further, described Radix pseudostellariae cyclic peptides refers to the cyclic peptide compounds extracted from Radix Pseudostellariae, with white powder
Powder crystal form exists, and Radix Pseudostellariae has replenishing QI to invigorate the spleen, effect of promoting the production of body fluid for nourishing the lung, is usually used in weak after being ill,
Deficiency of both vital energy and Yin, effective active composition Radix pseudostellariae cyclic peptides therein has good antitumor, antibacterial, malaria, presses down
The multi-efficiencies such as platelet aggregation processed, anti-lipid peroxidation enzyme, estrogen sample, enhancing immunity.
Further, described stigmasterol is to extract from Semen sojae atricolor, prepares through physical purification, has nutriture value
The features such as value is high, physiologically active is strong, have good facilitation to the physiologically active of cancer therapy drug.
Further, described Mel refers to natural honey, multiple inorganic containing with human serum concentration comparable
Multiple organic acid and the trace element of useful health such as salt and vitamin, ferrum, calcium, copper, manganese, potassium, phosphorus,
The composition of blood can be effectively improved, eliminate tired out, improve sleep quality, strengthen human body resistance.
Further, described preservative refer to sodium benzoate, methyl hydroxybenzoate or sorbic acid one of which or
Several mixing, this type of preservative has good effect to various mycetes, yeast, antibacterial, destroys microorganism
Cell membrane, make intracellular protein denaturation, and respiratory enzyme system and the electron transmission of microbial cell can be suppressed
The activity of enzyme system, thus play good antiseptic effect.
Further, described surfactant refers to fatty acid monoglyceride, polyglycerol stearate or sucrose
Monolaurate one or several mixing therein, nonionic surfactant can accelerate in suspension
The sedimentation of particle, has the clarification obviously accelerating solution, promotes the effects such as filtration.
Further, described sweeting agent refers to mannitol, radix asparagi sweet extract, protein sugar one therein or several
Kind mixing, this type of sweeting agent is nontoxic, low grade fever, Gao Tian, will not fat, do not cause dental caries, will not cardiovascular
Disease, consumption is little, is suitable for oral absorption.
The preparation method of the oral liquid of a kind of CT of opposing radiation is:
(1) wogonin of described part by weight, etoposide, daidzein, limonene are joined it
The mass concentration of mixing quality 5 times amount be 55～75% ethanol solution in fully dissolve, obtained solution, standby；
(2) by the Radix pseudostellariae cyclic peptides of described part by weight, folic acid, stigmasterol, oleanolic acid, gallic acid,
Using jet mill to pulverize after the mixing of vitamin B1, arginine, lentinan, described jet mill is
Utilize at the joint of multiply high pressure draught material by impact several times, rub, shear and pulverize, the thing after pulverizing
Material moves to graded region with ascending air under blower fan draft effect, and it is strong that the stage turbine at high speed rotating produces
Under big centrifugal action, making thickness feed separation, the fine grained meeting granularity requirements enters whirlwind by grading wheel
Separator and cleaner unit are collected, and coarse granule drops to disintegrating area to be continued to pulverize, and the finish fineness obtained is high, mistake
300 mesh sieves, obtain hybrid medicine fine powder, then hybrid medicine fine powder join the purified water of described part by weight
Middle mechanical agitation 30～45min, rotating speed is 180～240r/min, is slowly added to (1) system in whipping process
Standby solution prepares hybrid medicine solution, standby；
(3) hybrid medicine solution prepared by (2) is carried out 105 DEG C of steam sterilizations 15～30min, to be cooled
To room temperature, add the preservative of described part by weight, surfactant, sweeting agent, Mel, pass through homogenizer
Homogenizing, is that 0.6～0.8 micron membrane filter filters with aperture, then according to every 10ml distinguishes fill, shading is sealed up for safekeeping,
I.e. obtain resisting the oral liquid of CT radiation.
The oral liquid of the present invention provides the benefit that: multi-medicament synergy, has and preferably resists radiation, increasing
Strong immunocompetence, prevent the effect of cell carcinogenesis, play antioxidant effect, strengthen body immunity, can improve
The hemopoietic system function of blood circulation and nervus centralis, alleviates isotope, the ray damage to body's immunity
Evil, vitimin supplement, aminoacid isoreactivity substance advantageous are in absorbing and opposing radioactive substance, and suppress immunity
The apoptosis of cell and there is radiation resistance.The oral liquid of the present invention is applicable to the crowd of Long Term Contact CT radiation,
Drug effect gentleness is stable, and without obvious adverse reaction, the disease caused prevention because of CT radiation has good clinic
Effect.
Detailed description of the invention
Embodiment 1:
A kind of oral liquid resisting CT radiation, described oral liquid specifically includes that wogonin 1.2%, too
Son ginseng cyclic peptide 2.4%, folic acid 0.8%, etoposide 0.05%, stigmasterol 0.6%, oleanolic acid 0.5%,
Daidzein 0.8%, gallic acid 0.2%, limonene 0.3%, vitamin B1 0.08%, arginine 0.15%,
Lentinan 1.4%, Mel 5%, surplus are purified water；Described oral liquid also includes adjuvant: preservative
0.02%, surfactant 0.35%, sweeting agent 3%.
Wherein, described Radix pseudostellariae cyclic peptides refers to the cyclic peptide compounds extracted from Radix Pseudostellariae, with white powder
Crystal form exists, and Radix Pseudostellariae has replenishing QI to invigorate the spleen, effect of promoting the production of body fluid for nourishing the lung, is usually used in weak after being ill, and gas is cloudy
Deficiency, effective active composition Radix pseudostellariae cyclic peptides therein has good antitumor, antibacterial, malaria, suppression blood
The multi-efficiency such as platelet gathering, anti-lipid peroxidation enzyme, estrogen sample, enhancing immunity.Described bean steroid
Alcohol is to extract from Semen sojae atricolor, prepares through physical purification, has features such as being of high nutritive value, physiologically active is strong,
The physiologically active of cancer therapy drug there is good facilitation.Described Mel refers to natural honey, contains and people
Plurality of inorganic salt that body serum-concentration is close and the multiple organic acid such as vitamin, ferrum, calcium, copper, manganese, potassium, phosphorus
With the trace element of useful health, the composition of blood can be effectively improved, eliminate tired out, improve sleep
Quality, strengthens human body resistance.Described preservative refers to sodium benzoate, this type of preservative to various mycetes,
Yeast, antibacterial have good effect, destroy the cell membrane of microorganism, make intracellular protein denaturation, and
The activity of the respiratory enzyme system of microbial cell and electron transmission enzyme system can be suppressed, thus play good anticorrosion effect
Really.Described surfactant refers to fatty acid monoglyceride, and nonionic surfactant can accelerate suspension
In the sedimentation of particle, have the clarification obviously accelerating solution, promote the effects such as filtration.Described sweet taste
Agent refers to mannitol, this type of sweeting agent is nontoxic, low grade fever, Gao Tian, will not fat, do not cause dental caries, Bu Zhixin
Angiopathy, consumption is little, is suitable for oral absorption.
The preparation method of the oral liquid of a kind of CT of opposing radiation is:
(1) wogonin of described part by weight, etoposide, daidzein, limonene are joined it
The ethanol solution that mass concentration is 55% of mixing quality 5 times amount fully dissolves, obtained solution, standby；
(2) by the Radix pseudostellariae cyclic peptides of described part by weight, folic acid, stigmasterol, oleanolic acid, gallic acid,
Using jet mill to pulverize after the mixing of vitamin B1, arginine, lentinan, described jet mill is
Utilize at the joint of multiply high pressure draught material by impact several times, rub, shear and pulverize, the thing after pulverizing
Material moves to graded region with ascending air under blower fan draft effect, and it is strong that the stage turbine at high speed rotating produces
Under big centrifugal action, making thickness feed separation, the fine grained meeting granularity requirements enters whirlwind by grading wheel
Separator and cleaner unit are collected, and coarse granule drops to disintegrating area to be continued to pulverize, and the finish fineness obtained is high, mistake
300 mesh sieves, obtain hybrid medicine fine powder, then hybrid medicine fine powder join the purified water of described part by weight
Middle mechanical agitation 30min, rotating speed is 180r/min, is slowly added to solution prepared by (1) in whipping process
Prepare hybrid medicine solution, standby；
(3) hybrid medicine solution prepared by (2) is carried out 105 DEG C of steam sterilization 15min, be cooled to room
The preservative of described part by weight, surfactant, sweeting agent, Mel is added after temperature, by homogenizer homogenizing,
Being that 0.6 micron membrane filter filters with aperture, then according to every 10ml fill respectively, shading is sealed up for safekeeping, is i.e. supported
The oral liquid of anti-CT radiation.
Embodiment 2:
A kind of oral liquid resisting CT radiation, described oral liquid specifically includes that wogonin 1.5%, too
Son ginseng cyclic peptide 2.8%, folic acid 1.2%, etoposide 0.07%, stigmasterol 0.8%, oleanolic acid 0.65%,
Daidzein 1%, gallic acid 0.35%, limonene 0.45%, vitamin B1 0.1%, arginine 0.25%,
Lentinan 1.6%, Mel 7%, surplus are purified water；Described oral liquid also includes adjuvant: preservative
0.035%, surfactant 0.45%, sweeting agent 4%.
Wherein, described Radix pseudostellariae cyclic peptides refers to the cyclic peptide compounds extracted from Radix Pseudostellariae, with white powder
Crystal form exists, and Radix Pseudostellariae has replenishing QI to invigorate the spleen, effect of promoting the production of body fluid for nourishing the lung, is usually used in weak after being ill, and gas is cloudy
Deficiency, effective active composition Radix pseudostellariae cyclic peptides therein has good antitumor, antibacterial, malaria, suppression blood
The multi-efficiency such as platelet gathering, anti-lipid peroxidation enzyme, estrogen sample, enhancing immunity.Described bean steroid
Alcohol is to extract from Semen sojae atricolor, prepares through physical purification, has features such as being of high nutritive value, physiologically active is strong,
The physiologically active of cancer therapy drug there is good facilitation.Described Mel refers to natural honey, contains and people
Plurality of inorganic salt that body serum-concentration is close and the multiple organic acid such as vitamin, ferrum, calcium, copper, manganese, potassium, phosphorus
With the trace element of useful health, the composition of blood can be effectively improved, eliminate tired out, improve sleep
Quality, strengthens human body resistance.Described preservative refers to methyl hydroxybenzoate, this type of preservative to various mycetes,
Yeast, antibacterial have good effect, destroy the cell membrane of microorganism, make intracellular protein denaturation, and
The activity of the respiratory enzyme system of microbial cell and electron transmission enzyme system can be suppressed, thus play good anticorrosion effect
Really.Described surfactant refers to polyglycerol stearate, and nonionic surfactant can accelerate suspension
In the sedimentation of particle, have the clarification obviously accelerating solution, promote the effects such as filtration.Described sweet taste
Agent refers to radix asparagi sweet extract, this type of sweeting agent is nontoxic, low grade fever, Gao Tian, will not fat, do not cause dental caries, will not
Cardiovascular disease, consumption is little, is suitable for oral absorption.
The preparation method of the oral liquid of a kind of CT of opposing radiation is:
(1) wogonin of described part by weight, etoposide, daidzein, limonene are joined it
The ethanol solution that mass concentration is 65% of mixing quality 5 times amount fully dissolves, obtained solution, standby；
(2) by the Radix pseudostellariae cyclic peptides of described part by weight, folic acid, stigmasterol, oleanolic acid, gallic acid,
Using jet mill to pulverize after the mixing of vitamin B1, arginine, lentinan, described jet mill is
Utilize at the joint of multiply high pressure draught material by impact several times, rub, shear and pulverize, the thing after pulverizing
Material moves to graded region with ascending air under blower fan draft effect, and it is strong that the stage turbine at high speed rotating produces
Under big centrifugal action, making thickness feed separation, the fine grained meeting granularity requirements enters whirlwind by grading wheel
Separator and cleaner unit are collected, and coarse granule drops to disintegrating area to be continued to pulverize, and the finish fineness obtained is high, mistake
300 mesh sieves, obtain hybrid medicine fine powder, then hybrid medicine fine powder join the purified water of described part by weight
Middle mechanical agitation 37.5min, rotating speed is 210r/min, is slowly added to solution prepared by (1) in whipping process
Prepare hybrid medicine solution, standby；
(3) hybrid medicine solution prepared by (2) is carried out 105 DEG C of steam sterilization 22.5min, be cooled to
The preservative of described part by weight, surfactant, sweeting agent, Mel is added after room temperature, equal by homogenizer
Matter, is that 0.7 micron membrane filter filters with aperture, then according to every 10ml fill respectively, shading is sealed up for safekeeping, to obtain final product
Oral liquid to opposing CT radiation.
Embodiment 3:
A kind of oral liquid resisting CT radiation, described oral liquid specifically includes that wogonin 1.8%, too
Son ginseng cyclic peptide 3.2%, folic acid 1.6%, etoposide 0.09%, stigmasterol 1.0%, oleanolic acid 0.8%,
Daidzein 1.2%, gallic acid 0.5%, limonene 0.6%, vitamin B1 0.12%, arginine 0.35%,
Lentinan 1.8%, Mel 9%, surplus are purified water；Described oral liquid also includes adjuvant: preservative
0.05%, surfactant 0.55%, sweeting agent 5%.
Wherein, described Radix pseudostellariae cyclic peptides refers to the cyclic peptide compounds extracted from Radix Pseudostellariae, with white powder
Crystal form exists, and Radix Pseudostellariae has replenishing QI to invigorate the spleen, effect of promoting the production of body fluid for nourishing the lung, is usually used in weak after being ill, and gas is cloudy
Deficiency, effective active composition Radix pseudostellariae cyclic peptides therein has good antitumor, antibacterial, malaria, suppression blood
The multi-efficiency such as platelet gathering, anti-lipid peroxidation enzyme, estrogen sample, enhancing immunity.Described bean steroid
Alcohol is to extract from Semen sojae atricolor, prepares through physical purification, has features such as being of high nutritive value, physiologically active is strong,
The physiologically active of cancer therapy drug there is good facilitation.Described Mel refers to natural honey, contains and people
Plurality of inorganic salt that body serum-concentration is close and the multiple organic acid such as vitamin, ferrum, calcium, copper, manganese, potassium, phosphorus
With the trace element of useful health, the composition of blood can be effectively improved, eliminate tired out, improve sleep
Quality, strengthens human body resistance.Described preservative refers to sorbic acid, and this type of preservative is to various mycetes, ferment
Female bacterium, antibacterial have good effect, destroy the cell membrane of microorganism, make intracellular protein denaturation, and can
The respiratory enzyme system of suppression microbial cell and the activity of electron transmission enzyme system, thus play good antiseptic effect.
Described surfactant refers to sucrose monolaurate, and nonionic surfactant can accelerate in suspension
The sedimentation of particle, has the clarification obviously accelerating solution, promotes the effects such as filtration.Described sweeting agent is
Finger protein sugar, this type of sweeting agent is nontoxic, low grade fever, Gao Tian, will not fat, do not cause dental caries, will not cardiovascular
Disease, consumption is little, is suitable for oral absorption.
The preparation method of the oral liquid of a kind of CT of opposing radiation is:
(1) wogonin of described part by weight, etoposide, daidzein, limonene are joined it
The ethanol solution that mass concentration is 75% of mixing quality 5 times amount fully dissolves, obtained solution, standby；
(2) by the Radix pseudostellariae cyclic peptides of described part by weight, folic acid, stigmasterol, oleanolic acid, gallic acid,
Using jet mill to pulverize after the mixing of vitamin B1, arginine, lentinan, described jet mill is
Utilize at the joint of multiply high pressure draught material by impact several times, rub, shear and pulverize, the thing after pulverizing
Material moves to graded region with ascending air under blower fan draft effect, and it is strong that the stage turbine at high speed rotating produces
Under big centrifugal action, making thickness feed separation, the fine grained meeting granularity requirements enters whirlwind by grading wheel
Separator and cleaner unit are collected, and coarse granule drops to disintegrating area to be continued to pulverize, and the finish fineness obtained is high, mistake
300 mesh sieves, obtain hybrid medicine fine powder, then hybrid medicine fine powder join the purified water of described part by weight
Middle mechanical agitation 45min, rotating speed is 240r/min, is slowly added to solution prepared by (1) in whipping process
Prepare hybrid medicine solution, standby；
(3) hybrid medicine solution prepared by (2) is carried out 105 DEG C of steam sterilization 30min, be cooled to room
The preservative of described part by weight, surfactant, sweeting agent, Mel is added after temperature, by homogenizer homogenizing,
Being that 0.8 micron membrane filter filters with aperture, then according to every 10ml fill respectively, shading is sealed up for safekeeping, is i.e. supported
The oral liquid of anti-CT radiation.
Experimental verification:
1, taking experiment mice 200, male and female have, body weight 150-180g, be divided into group 1 of taking medicine, group of taking medicine 2,
Group 3 of taking medicine and blank group four groups, often group 50, the physiological performance such as often group mice sign is good, body weight are as good as
Often, there is comparability.
2, give take medicine group 1, group of taking medicine 2, take medicine group 3 respectively use the embodiment of the present invention 1, embodiment 2,
The oral liquid of embodiment 3 preparation carries out gastric infusion, and blank group does not take any medicine, every day secondary, continuously
Take three weeks, during testing, all mices are placed with in the environment of x-ray bombardment every day, irradiate every time
10min, irradiates once, observe the life state often organizing mice every day, and to the most dead little after experiment terminates
Mus carries out dissecting inspection, and statistics is because the mice sign of X-ray impact is abnormal.
3, experimental data statistics:
| Group | Number of mice | Healthy | Sign is abnormal | Dead | Healthy rate |
| Take medicine group 1 | 50 | 24 | 26 | 0 | 48.0% |
| Take medicine group 2 | 50 | 28 | 22 | 0 | 56.0% |
| Take medicine group 3 | 50 | 22 | 28 | 0 | 44.0% |
| Blank group | 50 | 8 | 23 | 19 | 16.0% |
4, result: by the experimental data in upper table it can be seen that the present invention prepare opposing CT radiation mouth
Taking liquid and have good effect for opposing radiation, healthy rate ratio does not use any medicine, completely by autoimmune merit
Radiation can be resisted and to exceed about 3 times, and dead mouse does not occurs, it is seen that the effect of opposing CT radiation is very
Substantially, can relieved use.
Last it is noted that above example is only in order to illustrate technical scheme, it is not intended to limit；
Although being described in detail the present invention with reference to previous embodiment, those of ordinary skill in the art should manage
Solve: the technical scheme described in previous embodiment still can be modified by it, or to wherein portion of techniques
Feature carries out equivalent；And these amendments or replacement, do not make the essence of appropriate technical solution depart from this
The spirit and scope of bright embodiment technical scheme.
Claims (8)
1. the oral liquid resisting CT radiation, it is characterised in that described oral liquid specifically includes that the Chinese
Baicalin 1.2～1.8%, Radix pseudostellariae cyclic peptides 2.4～3.2%, folic acid 0.8～1.6%, etoposide 0.05～
0.09%, stigmasterol 0.6～1.0%, oleanolic acid 0.5～0.8%, daidzein 0.8～1.2%, Galla Turcica (Galla Helepensis)
Acid 0.2～0.5%, limonene 0.3～0.6%, vitamin B1 0.08～0.12%, arginine 0.15～0.35%,
Lentinan 1.4～1.8%, Mel 5～9%, surplus are purified water；Described oral liquid also includes adjuvant:
Preservative 0.02～0.05%, surfactant 0.35～0.55%, sweeting agent 3～5%.
A kind of oral liquid resisting CT radiation the most as claimed in claim 1, it is characterised in that described
Radix pseudostellariae cyclic peptides refers to the cyclic peptide compounds extracted from Radix Pseudostellariae, exists with white powder crystal form.
A kind of oral liquid resisting CT radiation the most as claimed in claim 1, it is characterised in that described
Stigmasterol extracts from Semen sojae atricolor.
A kind of oral liquid resisting CT radiation the most as claimed in claim 1, it is characterised in that described
Mel refers to natural honey.
A kind of oral liquid resisting CT radiation the most as claimed in claim 1, it is characterised in that described
Preservative refers to sodium benzoate, methyl hydroxybenzoate or sorbic acid one of which or several mixing.
A kind of oral liquid resisting CT radiation the most as claimed in claim 1, it is characterised in that described
Surfactant refers to fatty acid monoglyceride, polyglycerol stearate or sucrose monolaurate one therein
Or several mixing.
A kind of oral liquid resisting CT radiation the most as claimed in claim 1, it is characterised in that described
Sweeting agent refers to one or several the mixing therein of mannitol, radix asparagi sweet extract, protein sugar.
8. a kind of oral liquid resisting CT radiation as described in claim 1～7 any one, its feature exists
In preparation method it is:
(1) wogonin of described part by weight, etoposide, daidzein, limonene are joined it
The mass concentration of mixing quality 5 times amount be 55～75% ethanol solution in fully dissolve, obtained solution, standby；
(2) by the Radix pseudostellariae cyclic peptides of described part by weight, folic acid, stigmasterol, oleanolic acid, gallic acid,
Use jet mill to pulverize after the mixing of vitamin B1, arginine, lentinan, cross 300 mesh sieves, obtain
Hybrid medicine fine powder, then hybrid medicine fine powder is joined mechanical agitation in the purified water of described part by weight
30～45min, rotating speed is 180～240r/min, is slowly added to solution system prepared by (1) in whipping process
Obtain hybrid medicine solution, standby；
(3) hybrid medicine solution prepared by (2) is carried out 105 DEG C of steam sterilizations 15～30min, to be cooled
To room temperature, add the preservative of described part by weight, surfactant, sweeting agent, Mel, pass through homogenizer
Homogenizing, is that 0.6～0.8 micron membrane filter filters with aperture, then according to every 10ml distinguishes fill, shading is sealed up for safekeeping,
I.e. obtain resisting the oral liquid of CT radiation.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610286995.1A CN105853994A (en) | 2016-05-03 | 2016-05-03 | Oral liquid for resisting CT radiation and preparation method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610286995.1A CN105853994A (en) | 2016-05-03 | 2016-05-03 | Oral liquid for resisting CT radiation and preparation method thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN105853994A true CN105853994A (en) | 2016-08-17 |
Family
ID=56629868
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201610286995.1A Pending CN105853994A (en) | 2016-05-03 | 2016-05-03 | Oral liquid for resisting CT radiation and preparation method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN105853994A (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN110237232A (en) * | 2019-07-30 | 2019-09-17 | 广东海洋大学 | Radix pseudostellariae cyclic peptides B is improving the application in memory and/or senile dementia prevention and cure |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103599125A (en) * | 2013-11-22 | 2014-02-26 | 吉林大学 | Anti-radiation and assistant anti-tumor drug and application |
-
2016
- 2016-05-03 CN CN201610286995.1A patent/CN105853994A/en active Pending
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103599125A (en) * | 2013-11-22 | 2014-02-26 | 吉林大学 | Anti-radiation and assistant anti-tumor drug and application |
Non-Patent Citations (7)
| Title |
|---|
| 于守洋: "《中国保健食品的进展》", 31 January 2001, 人民卫生出版社 * |
| 宛晓春: "《茶叶生物化学 第3版》", 31 August 2003, 中国农业出版社 * |
| 张奇: "《国防特色教材 军用药物制剂工程学》", 30 April 2012, 北京理工大学出版社 * |
| 汪多仁: "《有机食品营养强化剂》", 31 August 2008, 科技文献出版社 * |
| 肖小河: "《中国军事本草》", 31 July 2012, 人民军医出版社 * |
| 邱文清: "《常用中草药汇编 原植物彩色图鉴 下》", 31 May 2012, 中医古籍出版社 * |
| 黄红兵: "《抗肿瘤中药临床应用与图谱》", 31 January 2008, 广东科技出版社 * |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN110237232A (en) * | 2019-07-30 | 2019-09-17 | 广东海洋大学 | Radix pseudostellariae cyclic peptides B is improving the application in memory and/or senile dementia prevention and cure |
| CN110237232B (en) * | 2019-07-30 | 2020-09-01 | 广东海洋大学 | Application of radix pseudostellariae cyclic peptide B in improving memory and/or preventing and treating senile dementia |
| WO2021017925A1 (en) * | 2019-07-30 | 2021-02-04 | 广东海洋大学 | Application of radix pseudostellariae cyclic peptide b in improving memory and/or preventing and treating alzheimer's disease |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Aagenaes et al. | Hereditary recurrent intrahepatic cholestasis from birth. | |
| CN104739921B (en) | A kind of prescription lozenge and preparation method thereof for alleviating visual fatigue | |
| CN106255421A (en) | The manufacture method of Bulbus Allii fermentation composition and Bulbus Allii fermentation composition | |
| US11633444B2 (en) | Sporoderm-removed Ganoderma lucidum spore powder, granule and preparation method thereof | |
| CN106579460A (en) | Special clinical nutrition formula for fracture and preparation method thereof | |
| CN103800661B (en) | A kind of enhancing immunity, alleviating physical fatigue compositions and containing its preparation | |
| CN104585766A (en) | Composition as well as preparation method and application thereof | |
| CN101473943B (en) | Health-care food for improving memory function and preparation method thereof | |
| CN109316491A (en) | NK cell combines application of the mescenchymal stem cell in treatment hepatitis and liver fibrosis | |
| CN108902968A (en) | A kind of integration of drinking and medicinal herbs food addition formula and preparation method thereof for driving away toxoplasma | |
| CN103211063A (en) | Pabular health tea electuary for protecting gastric mucosa | |
| CN108014150A (en) | Application of the natural drug composition in anti anoxia and radiation-resistant medicine or food is prepared | |
| CN108096443B (en) | Medicine for eliminating toxins in livestock and poultry and improving immunity of organism, preparation method and application thereof | |
| CN105853994A (en) | Oral liquid for resisting CT radiation and preparation method thereof | |
| CN105410569A (en) | Preparation method of mulberry drink with protective effect on alcoholic liver injury | |
| CN102552639A (en) | Traditional Chinese medicine possessing function for alleviating asthenopia and its preparation method | |
| CN100381164C (en) | Medicine for treating radiation diseases | |
| CN108186794A (en) | A kind of Chinese medicine composition for treating malignant tumour and its preparation method and application | |
| CN107361269A (en) | A kind of lycium ruthenicum saline cistanche composite beverage and preparation method thereof | |
| Yuca et al. | Aural live foreign bodies in children | |
| CN111528386B (en) | Hawthorn and natto solid beverage and preparation method thereof | |
| KR20160081012A (en) | Bitterness reduced red ginseng powder-containing health food composition and a method of manufacturing red ginseng | |
| CN107822983A (en) | A kind of radiation proof containing Ganoderma spore extract, acne-removing composition and preparation method thereof | |
| CN103845524B (en) | It is a kind of to treat the Chinese medicine composition and preparation method and purposes that kidney essence deficiency is demonstrate,proved after tumor radiotherapy, chemotherapy | |
| CN103355454A (en) | Food health-care tea electuary for preventing osteoporosis |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20160817 |
|
| RJ01 | Rejection of invention patent application after publication |